Zhi Hong

Dr. Zhi Hong

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
GWGrace Lai-Hung Wong
Grace Lai-Hung Wong
MYMan-Fung Yuen
Man-Fung Yuen
BLBing-Liang Lin
Bing-Liang Lin
Mark William DouglasMark William Douglas
Mark William Douglas
PHPeng Hu
Peng Hu
ZHZhi Hong
Zhi Hong
Functional cure is a goal for the treatment of chronic hepatitis B virus (HBV) infection; however, it is infrequently achieved with currently approved treatments. Here we provide a randomized evaluation of the small interfering RNA elebsiran, in combination with pegylated interferon alfa (PEG-IFNα), compared with PEG-IFNα monotherapy. In addition, this study evaluates the potential role of the HBV therapeutic vaccine BRII-179 in identifying immunologically responsive patients and improving hepatitis B surface antigen (HBsAg) loss rates. In part I (cohorts 1–3), virally suppressed participants with chronic HBV infection naive to BRII-179 were randomized 1:1:1 to receive 48 weekly doses of PEG-IFNα alone or in combination with 13 doses of elebsiran (200 mg or 100 mg) administered every 4 weeks. In part II (cohort 4), participants who had previously received 9 doses of elebsiran and BRII-179 in a prospective study (BRII-179-835-001) were categorized as BRII-179 anti-HBs responders or nonresponders based on their peak hepatitis B surface antibody (anti-HBs) levels (≥10 IU l−1 or <10 IU l−1, respectively) and subsequently received 13 doses of elebsiran 100 mg every 4 weeks plus 48 weekly doses of PEG-IFNα. Primary endpoints were HBsAg loss at the end of treatment (EOT) and 24 weeks post-EOT. In part I, at 24 weeks post-EOT, HBsAg loss was observed in 4 out of 19 (21.1%) participants receiving elebsiran 200 mg plus PEG-IFNα, 6 out of 18 (33.3%) participants receiving elebsiran 100 mg plus PEG-IFNα and 1 out of 18 (5.6%) participants receiving PEG-IFNα monotherapy. In part II, HBsAg loss was observed in 9 out of 31 (29.0%) participants at 24 weeks post-EOT, with a higher response among BRII-179 anti-HBs responders (8 out of 19 participants, 42.1%) compared with nonresponders (1 out of 12 participants, 8.3%). Elebsiran and PEG-IFNα combination therapy was generally safe and well tolerated. These results demonstrate an additive benefit of elebsiran when combined with PEG-IFNα in achieving sustained HBsAg loss. Furthermore, the increased HBsAg loss rate in BRII-179 anti-HBs responders suggests that BRII-179 may be a valuable tool for immunological profiling to optimize curative outcomes in patients with HBV infection. ClinicalTrials.gov registration: NCT05970289.

1 October 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
ZGZhiliang Gao
Zhiliang Gao
BLBing-Liang Lin
Bing-Liang Lin
GWGrace Lai-Hung Wong
Grace Lai-Hung Wong
MYMan-Fung Yuen
Man-Fung Yuen
YLYiwen Liu
Yiwen Liu
ZHZhi Hong
Zhi Hong
Background/Objectives: The clinical implications of HBsAg seroreversion following HBV functional cure therapies remain unclear. In two randomized phase 2 trials, therapeutic vaccine BRII-179 or siRNA elebsiran in combination with PEG-IFNα was evaluated versus PEG-IFNα monotherapy. This pooled analysis characterized the profile of HBsAg seroreversion and explored potential predictors. Methods: Participants achieving HBsAg loss at or shortly after end of treatment (EOT) were included. Binary endpoints were summarized with two-sided 95% CIs using the Clopper–Pearson method. Time-to-event analyses used Kaplan–Meier methods and Cox regression. Longitudinal associations were evaluated using logistic mixed-effects models. Results: Among 55 participants included, 24 (43.6%) experienced HBsAg seroreversion with modest magnitude; all peak levels were <100 IU/mL and most were 100 IU/L at EOT was associated with a lower risk of HBsAg seroreversion (HR 0.30, 95% CI 0.10–0.92; p = 0.036). Sustained anti-HBs positivity during post-EOT follow-up was consistently associated with durable HBsAg loss in longitudinal analyses. Exploratory Kaplan–Meier analyses showed numerically higher HBsAg seroreversion rates among HBeAg-positive participants and those with PEG-IFNα treatment duration <12 weeks after HBsAg loss, although these findings were not statistically significant. Conclusions: HBsAg seroreversion after PEG-IFNα with or without BRII-179 or elebsiran was mild and rarely associated with clinically relevant relapse. Higher EOT anti-HBs levels and persistent anti-HBs positivity were associated with greater durability of HBsAg loss and warrant prospective evaluation as a candidate biomarker for risk-adapted off-treatment monitoring.